Intracoronary stenting and risk for major adverse cardiac events during the first month

Helmut Schühlen, Adnan Kastrati, Josef Dirschinger, Jörg Hausleiter, Shpend Elezi, Anne Wehinger, Jürgen Pache, Martin Hadamitzky, Albert Schömig

Research output: Contribution to journalArticlepeer-review

173 Scopus citations

Abstract

Background - Our rationale for this study was to analyze the risk for procedural failure of attempted stenting and the risk for major adverse cardiac events (MACE) after success and to develop a risk stratification protocol for successful procedures. Methods and Results - Stenting was attempted in 2894 procedures during the 5-year study period (success in 98.3% of 3815 lesions). After failure, the MACE rate was 42.6%. The risk for failure was higher for lesions in the left circumflex coronary artery or in venous bypass grafts and after an acute occlusion before stenting; it increased with stenosis length or grade and decreased with vessel size and growing institutional experience in stenting. After success, death occurred in 0.8%, death or myocardial infarction in 2.0%, and any MACE in 3.6%. Independent risk factor's for MACE were older age, diabetes, acute myocardial infarction, unstable angina, impaired left ventricular function, residual dissections, stent overlap, longer stented segments, and a postprocedural regimen without ticlopidine. Procedural factors were substantially stronger predictors than operator-independent variables available before procedures. Overall, the risk declined after the first 3 days. Two major factors exhibited time-dependent variations of their influence: while residual dissections were the dominant risk factor within the first 3 days with a reduction after that, no protective effect of ticlopidine could be identified before day 3. From these results, we derived a risk stratification protocol for individual procedures. Conclusions - These results underscore the importance of optimal angiographic results and the need for antiplatelet regimens with immediate onset. Our risk stratification protocol may guide individual postprocedural care and allow us to compare risk profiles of different study populations and to devise quality control programs for stenting.

Original languageEnglish
Pages (from-to)104-111
Number of pages8
JournalCirculation
Volume98
Issue number2
DOIs
StatePublished - 14 Jul 1998

Keywords

  • Coronary disease
  • Platelet aggregation inhibitors
  • Risk factors
  • Stents

Fingerprint

Dive into the research topics of 'Intracoronary stenting and risk for major adverse cardiac events during the first month'. Together they form a unique fingerprint.

Cite this